ALS Researchers

Researchers: Merit Cudkowicz, MD, Robert H Brown, D.Phil, M.D. and Anthony J. Windebank, M.D.

Sponsor: Brainstorm-Cell Therapeutics

BrainStorm Cell Therapeutics

Study: A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS

Summary: This is a multi-center, randomized, double blind, placebo controlled study to evaluate the safety and efficacy of autologous (self) transplantation of Neurotrophic factors-secreting Mesenchymal Stromal Cells (MSC-NTF, NurOwn™) in patients with ALS .

MSC-NTF cells are a novel cell-therapeutic approach which is expected to effectively deliver Neurotrophic factors, which are potent survival factors for neurons, directly to the site of damage.

Study Status: Phase 2,  Active

 


Researcher: John A Kessler, MD

Sponsor: ViroMed Co.

Study: Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis

Summary: The purpose of this study is to determine the safety and tolerability of intramuscular injections of VM202 at different injection sites in people with amyotrophic lateral sclerosis.

Study Status: Phase 1,  Active

 


If you feel that your research should be listed on this page, please contact us at thecureprize@gmail.com

Updated: 05/28/2015